These findings suggest that pharmacologic targeting of IL-22 signaling may suppress BC expansion and parenchymal remodeling in lung diseases associated with proximalization of the injured alveolar epithelium, such as following severe respiratory viral infection or in patients with chronic interstitial lung disease. The gene discussed is IL22; the disease is lung disorder.